Author: Papadopoulos, Christodoulos; Patoulias, Dimitrios; Teperikidis, Eleftherios; Mouselimis, Dimitrios; Tsarouchas, Anastasios; Toumpourleka, Maria; Boulmpou, Aristi; Bakogiannis, Constantinos; Doumas, Michael; Vassilikos, Vassilios P.
Title: Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review Cord-id: cjrvgvk9 Document date: 2020_8_4
ID: cjrvgvk9
Snippet: Coronavirus disease-19 (COVID-19) may result in serious complications involving several organ systems, including myocardial tissue. An exaggerated host inflammatory response, described as a cytokine storm, has been linked to play a major role in these complications. Colchicine and other pharmaceutical agents have been proposed to counter the cytokine storm and improve outcomes. In this exploratory review, we utilized a PubMed and Cochrane Database search aiming to identify the biochemical charac
Document: Coronavirus disease-19 (COVID-19) may result in serious complications involving several organ systems, including myocardial tissue. An exaggerated host inflammatory response, described as a cytokine storm, has been linked to play a major role in these complications. Colchicine and other pharmaceutical agents have been proposed to counter the cytokine storm and improve outcomes. In this exploratory review, we utilized a PubMed and Cochrane Database search aiming to identify the biochemical characteristics of the cytokine storm as well as to identify the potential effect of colchicine on these inflammatory biomarkers. The research yielded 30 reports describing the characteristics of the cytokine storm and 44 reports describing the effect of colchicine on various inflammatory biomarkers. According to our research, colchicine may be an agent of interest in the treatment of COVID-19 via its anti-inflammatory properties. However, there are potential drug interactions with cytochrome P450 3A4 inhibitors resulting in acute colchicine toxicities. Additionally, there is scarce evidence regarding the efficacy of colchicine in the acute phase of disease, since most trials evaluated its effect in chronic conditions. In this direction, our team proposes three different hypotheses for evaluating the place of colchicine in the treatment of COVID-19.
Search related documents:
Co phrase search for related documents- abdominal pain and ace angiotensin: 1, 2, 3, 4, 5, 6, 7
- abdominal pain and acute complication: 1, 2, 3, 4, 5, 6, 7, 8
- abdominal pain and acute exacerbation: 1, 2
- abdominal pain and acute phase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- abdominal pain and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
- abdominal pain and acute toxicity: 1, 2
- abdominal pain and adr adverse drug reaction: 1
- abdominal pain and liver injury: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
- abdominal pain and low recurrence: 1, 2, 3, 4
- abdominal pain and magnetic resonance: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- abdominal pain associate and acute phase: 1
- abdominal pain associate and acute respiratory syndrome: 1
- abstract title and acute phase: 1, 2, 3, 4, 5, 6, 7
- abstract title and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28
- abstract title and low recurrence: 1
- ace angiotensin and acute complication: 1, 2
- ace angiotensin and acute exacerbation: 1
- ace angiotensin and acute phase: 1, 2, 3, 4, 5
Co phrase search for related documents, hyperlinks ordered by date